Step 1 topics → Renal → ACE Inhibitors and ARBs — Renal Effects

ACE Inhibitors and ARBs — Renal Effects

USMLE Step 1 trap: Confuses ACEi as safe in bilateral RAS, missing that efferent arteriolar tone is the sole GFR-maintaining mechanism in that setting. In bilateral RAS, GFR is maintained by angiotensin II-mediated efferent arteriolar constriction; ACEi removes this compensation, causing acute GFR collapse and renal failure.

ACE inhibitors and ARBs are among the most-tested drug classes on USMLE Step 1, and the renal effects specifically come up in every format — pure mechanism recall, clinical vignettes, and passage-based reasoning. The core concept is this: angiotensin II preferentially constricts the efferent arteriole, raising intraglomerular pressure. ACEi blocks angiotensin II production; ARBs block its receptor. Both reduce efferent tone, drop intraglomerular pressure, lower GFR modestly, and reduce proteinuria. That shared hemodynamic endpoint is what unifies the two classes and what the exam exploits.

The tricky part is that the same mechanism that makes these drugs renoprotective in most patients makes them dangerous in specific settings — particularly bilateral renal artery stenosis. In that condition, the kidneys are entirely dependent on angiotensin II-driven efferent constriction to maintain any filtration pressure at all. Strip that away with an ACEi or ARB, and GFR collapses acutely. Students frequently misread this as 'ACEi lowers BP, lower BP is good for kidneys, therefore it's safe' — that's the exact wrong model. The other major confusion zone is interpreting any creatinine rise after starting an ACEi as a danger sign requiring discontinuation, when in fact a rise up to 30% is expected and acceptable.

USMLE Step 1 also tests the side effect profile differences between ACEi and ARBs, especially around cough. The cough is bradykinin-mediated — ACE normally degrades bradykinin, so blocking ACE lets bradykinin accumulate and irritate airways. ARBs don't touch ACE, so no bradykinin buildup, no cough. Students who memorize 'both block RAAS' sometimes incorrectly extend the cough side effect to ARBs. Angioedema is also bradykinin-mediated and is the reason you cannot simply switch to another ACEi if angioedema occurs — ARB is the switch.

From real student decks
73%have cards covering this topic
57%have mature cards

Common misconceptions

Common mistake
Wrong: ACE inhibitors are safe in bilateral renal artery stenosis because they lower blood pressure.
Right: In bilateral RAS, GFR is maintained by angiotensin II-mediated efferent arteriolar constriction; ACEi removes this compensation, causing acute GFR collapse and renal failure.
The error here is thinking about ACEi purely as an antihypertensive rather than as an agent that removes efferent arteriolar tone. In bilateral renal artery stenosis, blood flow into the glomerulus is already severely reduced by the stenosis — the only reason GFR is maintained at all is that angiotensin II is maximally constricting the efferent arteriole to build up filtration pressure downstream. When you give an ACEi or ARB, you eliminate that compensatory constriction, and filtration pressure collapses immediately. This is not a lowering-BP benefit; it is removal of the sole remaining mechanism keeping the kidney alive.
Common mistake
Wrong: Any rise in creatinine after starting an ACEi indicates the drug must be stopped.
Right: A creatinine rise of up to 30% after starting an ACEi is acceptable and expected due to reduced efferent tone; the drug should only be stopped if the rise exceeds this threshold or hyperkalemia develops.
A small creatinine rise after starting an ACEi is not a failure — it is the expected pharmacodynamic response. By dilating the efferent arteriole, ACEi reduces intraglomerular pressure and GFR drops slightly, which manifests as a modest creatinine rise. The clinical threshold is approximately 30%: rises within that range indicate the drug is doing its job and should be continued. Only if creatinine rises beyond that threshold, or if hyperkalemia develops, should you reconsider the drug. The reflex to stop ACEi at any creatinine elevation leads to undertreating patients who would benefit most from long-term renoprotection.
Common mistake
Wrong: ARBs cause the same dry cough as ACE inhibitors.
Right: ACEi-induced cough is caused by bradykinin accumulation (ACE normally degrades bradykinin); ARBs do not inhibit ACE and therefore do not cause cough, making them the alternative in ACEi-intolerant patients.
ACE has two substrates that matter here: angiotensin I (which it converts to angiotensin II) and bradykinin (which it degrades). Block ACE, and bradykinin accumulates — bradykinin is a potent irritant that triggers the dry, nonproductive cough seen in up to 15-20% of patients on ACEi. ARBs work entirely downstream at the angiotensin II receptor and have no effect on ACE enzyme activity, so bradykinin continues to be degraded normally. This is why ARBs are the preferred substitute when a patient cannot tolerate an ACEi due to cough — the same renal and cardiac benefits without the bradykinin-mediated side effect.
Common mistake
Wrong: ACEi reduces proteinuria only by lowering systemic blood pressure.
Right: ACEi reduces proteinuria primarily by dilating the efferent arteriole, which lowers intraglomerular pressure and reduces filtration of protein independent of systemic BP reduction.
Lowering systemic blood pressure does reduce proteinuria to some extent, but that is not the primary mechanism for ACEi. The key effect is local: by blocking angiotensin II, ACEi dilates the efferent arteriole specifically, which drops intraglomerular hydraulic pressure. Lower intraglomerular pressure means less mechanical force driving protein through the filtration barrier, reducing proteinuria even at blood pressures that are already well-controlled. This is why USMLE Step 1 emphasizes ACEi/ARBs as first-line in diabetic nephropathy regardless of whether the patient is hypertensive — the intraglomerular pressure reduction is the renoprotective mechanism, not just BP control.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Mechanism: How ACEi and ARBs each block the RAAS at different steps, and why both produce the same downstream hemodynamic effect — efferent arteriolar dilation and reduced intraglomerular pressure.
  2. Clinical correlate — bilateral RAS: Why ACEi and ARBs are absolutely contraindicated in bilateral renal artery stenosis, and what happens to GFR when efferent arteriolar tone is removed in that setting.
  3. Acceptable creatinine rise: How to distinguish an expected, benign creatinine rise after ACEi initiation (up to ~30%) from a clinically significant rise that requires stopping the drug.
  4. Indications and contraindications: When to use ACEi/ARBs (diabetic nephropathy, proteinuria, heart failure, hypertension) and when not to (bilateral RAS, pregnancy, hyperkalemia, history of angioedema).
  5. Side effect differentiation: Which adverse effects are unique to ACEi (dry cough, angioedema) due to bradykinin accumulation, and why ARBs do not share these effects — making ARBs the go-to alternative for ACEi-intolerant patients.

Can you avoid these mistakes?

A 58-year-old man with type 2 diabetes and a creatinine of 1.1 mg/dL is started on lisinopril. Two weeks later his creatinine is 1.4 mg/dL. What should you do, and why?
A patient with bilateral renal artery stenosis is started on an ACE inhibitor for hypertension. His creatinine doubles within one week. Explain the mechanism behind this deterioration — why does this happen in bilateral RAS but not in a patient with normal renal arteries?
A patient on enalapril develops a dry, persistent cough. You switch her to losartan. Will the cough resolve? Explain the pharmacological reason for your answer.
Explain why an ACE inhibitor reduces proteinuria in a diabetic patient whose blood pressure is already at goal on another antihypertensive — what mechanism is responsible, and what does it have to do with the efferent arteriole?

Related topics

GFR Determinants and Regulation Renin-Angiotensin-Aldosterone System Kidney Development (Pro-/Meso-/Metanephros) Congenital Renal Anomalies Nephron Structure and Segments Renal Vasculature (Afferent / Efferent / Vasa Recta)

See how your Anki deck covers this topic.

Upload your deck for a free audit →